You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: RAFT PHARMACEUTICALS LLC Topic: NIAID
PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Applied Universal Dynamics, Corp. Topic: NIA
This project will develop a Socially-Assistive Robot (SAR) to provide cognitive training, in the form of learning to play the piano, to improve cognitive functioning and reduce feelings of loneliness in socially-isolated older adults. The SAR will administer cognitive training via guided practice on a set of standard piano lesson tasks designed to reflect particular cognitive functions: memory, at ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: GPB Scientific, Inc. Topic: 101
ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.SBC: EARNANO LLC Topic: NICHD
Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Development of a Neonatal Jaundice Treatment Accelerator by Circumferential Redirection of Unused Phototherapy Light onto the Infants Untreated Skin SurfaceSBC: Arbor Grace Inc. Topic: NICHD
PROJECT SUMMARY ABSTRACT Neonatal jaundice continues to be a significant global problem affectingof preterm andof term neonates while severe neonatal jaundice affects at leastneonates annuallyJaundice and jaundice related complications like Kernicterus Spectrum DisorderKDSare gaining recognition among the worldandapos s health policy leaders as an important area for further research and developmen ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41
Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community ParticipationSBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHD
Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic SyndromeSBC: Longeveron LLC Topic: NIA
The metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Neuro Devices, Inc. Topic: 100
The Bumps: A Device for Rapid, Non-Invasive Quantification of Touch Sensation Abstract !Our proposal describes an elegant device called the Bumps that quantifies finger pad touch sensation at low micron levels. The objectives are to diagnose peripheral neuropathy near its onset, when the possibility for reversal is highest, and to monitor either progression or reversal of neuropathy during treatme ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Renova Therapeutics, Inc. Topic: NHLBI
ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health